Get the Stockscreener App
0.7036
4.91%
-0.0363
Mustang Bio Inc stock is traded at $0.7036, with a volume of 61,839.
It is down -4.91% in the last 24 hours and down -4.53% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$0.7399
Open:
$0.737
24h Volume:
61,839
Relative Volume:
0.57
Market Cap:
$5.33M
Revenue:
-
Net Income/Loss:
$-2.72M
P/E Ratio:
-1.4655
EPS:
-0.4801
Net Cash Flow:
$-4.88M
1W Performance:
+0.09%
1M Performance:
-4.53%
6M Performance:
-39.34%
1Y Performance:
-73.75%
1-Day Range:
$0.6822
$0.737
1-Week Range:
$0.6654
$0.74
52-Week Range:
$0.5306
$3.00
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
95 SAWYER RD, WALTHAM, NY
Compare MBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
0.7036 | 5.33M | 0 | -2.72M | -4.88M | -0.4801 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Deep Losses Overshadow Progress in CAR T PipelineUpward Estimate Revision - dars.gov.et
Mustang Bio (MBIO) Q1 2026 earnings summary - Quartr
Mustang Bio (MBIO) Proxy Filing Summary - Quartr
Mustang Bio (MBIO) Registration Filing Summary - Quartr
TDW Q1 2026 Earnings: Significant EPS Miss Despite Stock GainDebt Analysis Report - dars.gov.et
MSN Money - MSN
MBIO Should I Buy - Intellectia AI
MBIO Q4 2024 Earnings: Massive EPS Miss as Clinical-Stage Biotech Reports No RevenueEarnings Revision Report - dars.gov.et
Enterprise value to EBIT forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBITDA forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBIT forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to book forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Enterprise value to revenue forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Traders are paying attention to the gapping stocks in Friday's session. - ChartMill
Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mustang Bio, Inc. Actuals & Estimates (NASDAQ:MBIO) - TradingView
Silver Tiger Metals Inc.'s (TSE:SLVR) Path To Profitability - simplywall.st
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Ongoing Clinical-Stage Challenges - dars.gov.et
MBIO Q4 2024 Earnings: Wider-than-Expected Loss Amid Clinical ProgressEarnings Risk Report - dars.gov.et
Glioma Pipeline Insights Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
Mustang Bio Inc (MBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mustang Bio Inc (MBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mustang Bio Inc (MBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mustang Bio Inc (MBIO) Institutional Confidence - TradingKey
Mustang Bio Inc (MBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SpaceX IPO Leaves Retail Investors Scrambling as Tiny Allocations Spur Mixed ReactionsBuyback Announcement Report - newsline.com
CNET Q3 2011 Earnings: EPS Misses by 65.4% Amid Uncertain Revenue DisclosureEarnings Growth Analysis - newsline.com
Getty Images Holdings (GETY) Slides 2.55% as Stock Nears Key Support at $0.70VWAP Breakout - newsline.com
MBIO Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: EPS Misses by Wide Margin Amid No Revenue; Stock DeclinesEstimate Uncertainty - Město Břeclav
ADXN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
American Airlines (AAL) Q1 2026 Earnings: EPS Beats Estimates Despite Net LossHealthcare Earnings Report - dars.gov.et
MBIO Q4 2024 Earnings: Substantial EPS Miss Reflects Clinical-Stage Development CostsFull Year Guidance - dars.gov.et
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CCL Q1 2026 Earnings: EPS Surpasses Estimates by 7.3%, Shares Gain 2.5%Cash Flow Report - newsline.com
Spring Valley Acquisition Corp. III (SVAC) Holds Near Support Amid Modest DeclineRTH Profile - newsline.com
Mustang Bio (MBIO) Moves Higher, Testing Key Resistance at $0.83Analyst Downgrade Signals - newsline.com
Water Utility Fined £1.8 Million Over Parasite Outbreak in DevonProfit Announcement - newsline.com
JATT Price Today: JATT II Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC
Mustang Bio Q4 2024 Earnings: Massive EPS Miss Highlights Cash Burn and Clinical Progress UncertaintyCFO Commentary Report - newsline.com
Mustang Bio (MBIO) Q4 2024 Earnings: Wider-Than-Expected Losses Offset by Positive Stock Movement Amid Pipeline FocusGuidance Accuracy Score - newsline.com
WaFd Inc. (WAFD) Q1 2026 Earnings: EPS Tops Estimates; Small Decline in StockFree Cash Flow Trends - The Legal Advocate
Real Asset Acquisition Corp. Unit (RAAQU) Holds Steady Near Support as Consolidation Phase ContinuesInvestment Factor - The Legal Advocate
Is Mustang Bio (MBIO) a Hidden Gem in the Microbiome Revolution, or a Risky Bet - Kavout
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):